8-K: Starling Oncology Reports Strong Q2 2026 Results, Raises Guidance

Starling Oncology announced robust second quarter 2026 financial results, with revenue up 34.6% and a significant improvement in Adjusted EBITDA, leading to an upward revision of full-year guidance.

Summary

• Starling Oncology reported a strong second quarter ended June 30, 2026, with consolidated revenue reaching $161.3 million, a 34.6% increase year-over-year.
• Gross profit saw a substantial rise of 55.2% to $27.2 million.
• The company reduced its net loss to $9.8 million from $17.0 million in the prior year's quarter.
• Basic and diluted loss per share improved to $(0.08) from $(0.15).
• Adjusted EBITDA turned positive at $229 thousand, a significant improvement from a negative $4.1 million in Q2 2025.
• The company has updated its full-year 2026 guidance, increasing revenue, gross profit, and Adjusted EBITDA projections.
• Key operational highlights include record Part D fills in Specialty Pharmacy, driving revenue growth, and securing exclusivity in California with a major partner, adding approximately 230,000 capitated lives.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, driven by strong revenue growth, improved profitability metrics, and an optimistic updated guidance for the full year.

Positives

• Consolidated revenue increased by 34.6% to $161.3 million in Q2 2026 compared to Q2 2025.
• Gross profit increased by 55.2% to $27.2 million.
• Net loss decreased to $9.8 million from $17.0 million.
• Adjusted EBITDA improved significantly, turning positive at $229 thousand from a negative $4.1 million.
• Specialty Pharmacy revenue grew by 58% due to record Part D fills and new capitated lives.
• Exclusivity agreement in California with a large partner added approximately 230,000 capitated lives.
• Full-year 2026 revenue guidance was raised to $650-$670 million from $630-$650 million.
• Full-year 2026 Adjusted EBITDA guidance was raised to $2-$7 million from $0-$9 million.

Negatives

• The company still reported a net loss of $9.8 million for the second quarter of 2026.
• Basic and diluted loss per share remained negative at $(0.08).

Risks

• The outlook information does not account for unanticipated developments or changes in the operating or economic environment.
• Recent tariff rate increases and exchange rate changes could adversely affect world trade and the company's outlook.
• Forward-looking statements are subject to numerous risks and uncertainties, including those discussed in the company's SEC filings, which could cause actual results to differ materially.

Future Outlook

The company has raised its full-year 2026 guidance for revenue to $650-$670 million, gross profit to $105-$110 million, and Adjusted EBITDA to $2-$7 million. Free Cash Flow guidance remains unchanged at $5-$15 million. For the third quarter of 2026, Adjusted EBITDA is anticipated to be between $500 thousand and $1.5 million.

Management Comments

• "The second quarter of 2026 was a milestone quarter for our company, with revenue up 35% year over year and Adjusted EBITDA turning positive in Q2."
• "We signed our first delegated contracts outside of Florida, in Nevada and Oregon, and reached an exclusivity agreement with one of our largest partners across California. Both of these achievements will drive robust capitated revenue growth going forward."
• "In mid-August, we are launching our new provider portal, Starling Oncology NexusTM, which we expect will deepen provider engagement and further support adherence to our clinical pathways."
• "Given this momentum, we are raising our full-year outlook, and remain confident in our path to sustained positive Adjusted EBITDA as we move forward as Starling Oncology."

Industry Context

StockSavvy.ai notes that Starling Oncology's performance aligns with the trend of value-based care models gaining traction in the oncology sector. The reported revenue growth, particularly in specialty pharmacy and through capitated contracts, reflects the company's strategy to manage costs and improve patient outcomes within these frameworks. The launch of the Starling Nexus provider portal is a strategic move to enhance network physician engagement, a critical factor for success in value-based arrangements.

Comparison to Industry Standards

• The reported revenue growth of 34.6% for Q2 2026 is significantly higher than the typical growth rates seen in the broader healthcare services sector, which often range from single digits to low double digits.
• The improvement in Adjusted EBITDA, turning positive from a significant loss, indicates a strong operational leverage and cost management, which is a key performance indicator for companies transitioning to value-based care models.
• The Medical Loss Ratio (MLR) for capitated contracts was 85.5% in Q2 2026, which is within the expected range of 80%-90% for the next twelve months. This metric is crucial for assessing the profitability of capitated arrangements and is closely watched by investors in managed care and value-based providers.
• While specific competitor data is not provided in the filing, the company's focus on community oncology and value-based care places it in a segment that is actively seeking to differentiate from traditional fee-for-service models, aiming for better patient outcomes and cost efficiencies.

Stakeholder Impact

• Shareholders: Positive impact expected from improved financial performance, increased revenue, and raised full-year guidance, potentially leading to increased shareholder value.
• Employees: Continued growth and operational improvements may lead to increased job security and potential for expansion.
• Partners/Providers: The launch of Starling Nexus aims to strengthen provider engagement and adherence to clinical pathways, potentially improving collaboration and efficiency.
• Patients: The focus on value-based care and clinical pathways aims to improve patient outcomes and care coordination.

Next Steps

• Launch of the proprietary provider portal, Starling Nexus, in mid-August.
• Onboarding and ramping Florida delegated lives in the third quarter of 2026.
• Hosting a conference call on August 6, 2026, to discuss results and outlook.

Key Dates

Recommendation

While the Q2 results and raised guidance are positive, the company still operates at a net loss. The significant improvement in Adjusted EBITDA is encouraging, but sustained profitability and continued execution on growth strategies are necessary to warrant a stronger buy recommendation. The current 'hold' reflects a balanced view of the progress made against the remaining challenges.

Keywords

oncology, value-based care, specialty pharmacy, capitated revenue, financial results, guidance update, Adjusted EBITDA, revenue growth